Drug Profile
Research programme: optogenetic therapy - Beacon Therapeutics/Bionic Sight
Alternative Names: AAV-based optogenetic therapiesLatest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Applied Genetic Technologies Corporation; Bionic Sight
- Developer Beacon Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Blindness
Most Recent Events
- 07 Jul 2022 Optogenetic therapy is still in preclinical development in USA (Ophthalmic) (Applied Genetic Technologies Corporation pipeline, July 2022)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Blindness in USA (Ophthalmic)
- 31 Jan 2020 Optogenetic therapy is still in preclinical trials for Blindness (Opthalmic) in USA